First Patient Dosed in INmune Bio’s Phase1b Trial Testing XPro1595 Anti-inflammatory Compound for Alzheimer’s

First Patient Dosed in INmune Bio’s Phase1b Trial Testing XPro1595 Anti-inflammatory Compound for Alzheimer’s
INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead of targeting amyloid plaques — or clumps of misfolded proteins — in the brains of Alzheimer's patients, XPro1595 is designed to inhibit neuroinflammation, an earlier step in the disease. Neuroinflammation has been linked to the loss of neuronal communication, neuronal cell death, cognitive impairment, and plaque formation. Occurring in the central nervous system, which consists of the brain and spinal cord, neuroinflammation is a key event underlying AD. It is mediated by an excessive activation of glial cells — nerve cells that surround and support neurons — and the overproduction of small pro-inflammatory molecules called cytokines. The levels of tumor necrosis factor (TNF), a pro-inflammatory cytokine, ar
Subscribe or to access all post and page content.